Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Methodological quality of COVID-19 clinical research

Open access
Jung, Richard G., Di Santo, Pietro, Clifford, Cole, Prosperi-Porta, Graeme, Skanes, Stephanie, Hung, Annie, Parlow, Simon, Visintini, Sarah, Ramirez, F. Daniel, Simard, Trevor, Hibbert, Benjamin · 2021 · Nature Communications

Published version of a preprint

Abstract

The COVID-19 pandemic began in early 2020 with major health consequences. While a need to disseminate information to the medical community and general public was paramount, concerns have been raised regarding the scientific rigor in published reports. We performed a systematic review to evaluate the methodological quality of currently available COVID-19 studies compared to historical controls. A total of 9895 titles and abstracts were screened and 686 COVID-19 articles were included in the final analysis. Comparative analysis of COVID-19 to historical articles reveals a shorter time to acceptance (13.0[IQR, 5.0–25.0] days vs. 110.0[IQR, 71.0–156.0] days in COVID-19 and control articles, respectively; p < 0.0001). Furthermore, methodological quality scores are lower in COVID-19 articles across all study designs. COVID-19 clinical studies have a shorter time to publication and have lower methodological quality scores than control studies in the same journal. These studies should be revisited with the emergence of stronger evidence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-21220-5

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Literature search and selection of COVID-19 articles. A total of 14787 articles were identified and 4892 duplicate articles were removed. Overall, 9895 articles were screened by title and abstract leaving 794 articles for full-text screening. Over 108 articles were excluded, leaving a total of 686 articles that underwent methodological quality assessment.
Fig. 1 Literature search and selection of COVID-19 articles. A total of 14787 articles were identified and 4892 duplicate articles were removed. Overall, 9895 articles were screened by title and abstract leaving 794 articles for full-text screening. Over 108 articles were excluded, leaving a total of 686 articles that underwent methodological quality assessment.CC BY · PubMed Central
Fig. 2 COVID-19 clinical literature quality assessment. A Distribution of COVID-19 case series studies scored using the Murad tool (n = 380). B Distribution of COVID-19 cohort studies scored using the Newcastle–Ottawa Scale (n = 199). C Distribution of COVID-19 case–control studies scored using the Newcastle–Ottawa Scale (n = 38). D Distribution of COVID-19 diagnostic studies scored using the QUADAS-2 tool (n = 63). In panel D, blue represents low risk of bias and orange represents high risk of bias.
Fig. 2 COVID-19 clinical literature quality assessment. A Distribution of COVID-19 case series studies scored using the Murad tool (n = 380). B Distribution of COVID-19 cohort studies scored using the Newcastle–Ottawa Scale (n = 199). C Distribution of COVID-19 case–control studies scored using the Newcastle–Ottawa Scale (n = 38). D Distribution of COVID-19 diagnostic studies scored using the QUADAS-2 tool (n = 63). In panel D, blue represents low risk of bias and orange represents high risk of bias.CC BY · PubMed Central
Fig. 3 Differences in methodological quality scores in COVID-19 by secondary outcomes. A When stratified by time of acceptance (13.0 days), increased time of acceptance was associated with higher case series score (n = 186 for <13 days and n = 193 for >=13 days; p = 0.02). B Increased time of acceptance was associated with higher NOS cohort score (n = 112 for <13 days and n = 144 for >=13 days; p = 0.003). C No difference in time of acceptance and case–control score was observed (n = 18 for <13 days and n = 27 for >=13 days; p = 0.34). D No difference in time of acceptance and diagnostic risk of bias (QUADAS-2) was observed (n = 43 for <13 days and n = 33 for >=13 days; p = 0.23). E When stratified by impact factor (IF ≥10), high IF was associated with higher case series score (n = 466 for low IF and n = 60 for high IF; p < 0.0001). F High IF was associated with higher NOS cohort score (n = 262 for low IF and n = 68 for high IF; p = 0.01). G No difference in IF and case–control score was observed (n = 62 for low IF and n = 2 for high IF; p = 0.052). H No difference in IF and QUADAS-2 was observed (n = 101 for low IF and n = 2 for high IF; p = 0.93). I When stratified by geographical region, no difference in geographical region and case series score was observed (n = 276 Asia/Oceania, n = 135 Americas, and n = 143 Europe/Africa; p = 0.10). J Geographical region was associated with differences in cohort score (n = 177 Asia/Oceania, n = 81 Americas, and n = 89 Europe/Africa; p = 0.01). K No difference in geographical region and case–control score was observed (n = 37 Asia/Oceania, n = 13 Americas, and n = 14 Europe/Africa; p = 0.81). L No difference in geographical region and QUADAS-2 was observed (n = 49 Asia/Oceania, n = 28 Americas, and n = 28 Europe/Africa; p = 0.34). In panels A–D, orange represents lower median time of acceptance and blue represents high median time of acceptance. In panels E–H, red is low impact factor and blue is high impact factor. In panels I–L, orange represents Asia/Oceania, blue represents Americas, and brown represents Europe. Differences in distributions were analysed by two-sided Kruskal–Wallis test. Differences in diagnostic risk of bias were quantified by Chi-squares test. p < 0.05 was considered statistically significant.
Fig. 3 Differences in methodological quality scores in COVID-19 by secondary outcomes. A When stratified by time of acceptance (13.0 days), increased time of acceptance was associated with higher case series score (n = 186 for <13 days and n = 193 for >=13 days; p = 0.02). B Increased time of acceptance was associated with higher NOS cohort score (n = 112 for <13 days and n = 144 for >=13 days; p = 0.003). C No difference in time of acceptance and case–control score was observed (n = 18 for <13 days and n = 27 for >=13 days; p = 0.34). D No difference in time of acceptance and diagnostic risk of bias (QUADAS-2) was observed (n = 43 for <13 days and n = 33 for >=13 days; p = 0.23). E When stratified by impact factor (IF ≥10), high IF was associated with higher case series score (n = 466 for low IF and n = 60 for high IF; p < 0.0001). F High IF was associated with higher NOS cohort score (n = 262 for low IF and n = 68 for high IF; p = 0.01). G No difference in IF and case–control score was observed (n = 62 for low IF and n = 2 for high IF; p = 0.052). H No difference in IF and QUADAS-2 was observed (n = 101 for low IF and n = 2 for high IF; p = 0.93). I When stratified by geographical region, no difference in geographical region and case series score was observed (n = 276 Asia/Oceania, n = 135 Americas, and n = 143 Europe/Africa; p = 0.10). J Geographical region was associated with differences in cohort score (n = 177 Asia/Oceania, n = 81 Americas, and n = 89 Europe/Africa; p = 0.01). K No difference in geographical region and case–control score was observed (n = 37 Asia/Oceania, n = 13 Americas, and n = 14 Europe/Africa; p = 0.81). L No difference in geographical region and QUADAS-2 was observed (n = 49 Asia/Oceania, n = 28 Americas, and n = 28 Europe/Africa; p = 0.34). In panels A–D, orange represents lower median time of acceptance and blue represents high median time of acceptance. In panels E–H, red is low impact factor and blue is high impact factor. In panels I–L, orange represents Asia/Oceania, blue represents Americas, and brown represents Europe. Differences in distributions were analysed by two-sided Kruskal–Wallis test. Differences in diagnostic risk of bias were quantified by Chi-squares test. p < 0.05 was considered statistically significant.CC BY · PubMed Central
Fig. 4 Differences in methodological quality scores in COVID-19 compared to historical control articles. A Time to acceptance was reduced in COVID-19 articles compared to control articles (13.0 [IQR, 5.0–25.0] days vs. 110.0 [IQR, 71.0–156.0] days, n = 347 for COVID-19 and n = 414 for controls; p < 0.0001). B When compared to historical control articles, COVID-19 articles were associated with lower case series score (n = 277 for COVID-19 and n = 277 for controls; p < 0.0001). C COVID-19 articles were associated with lower NOS cohort score compared to historical control articles (n = 174 for COVID-19 and n = 174 for controls; p < 0.0001). D COVID-19 articles were associated with lower NOS case–control score compared to historical control articles (n = 32 for COVID-19 and n = 32 for controls; p = 0.003). E COVID-19 articles were associated with higher diagnostic risk of bias (QUADAS-2) compared to historical control articles (n = 53 for COVID-19 and n = 53 for controls; p = 0.02). For panel A, boxplot captures 5, 25, 50, 75 and 95% from the first to last whisker. Orange represents COVID-19 articles and blue represents control articles. Two-sided Mann–Whitney U-test was conducted to evaluate differences in time to acceptance between COVID-19 and control articles. Differences in study quality scores were evaluated by two-sided Kruskal–Wallis test. Differences in diagnostic risk of bias were quantified by Chi-squares test. p < 0.05 was considered statistically significant.
Fig. 4 Differences in methodological quality scores in COVID-19 compared to historical control articles. A Time to acceptance was reduced in COVID-19 articles compared to control articles (13.0 [IQR, 5.0–25.0] days vs. 110.0 [IQR, 71.0–156.0] days, n = 347 for COVID-19 and n = 414 for controls; p < 0.0001). B When compared to historical control articles, COVID-19 articles were associated with lower case series score (n = 277 for COVID-19 and n = 277 for controls; p < 0.0001). C COVID-19 articles were associated with lower NOS cohort score compared to historical control articles (n = 174 for COVID-19 and n = 174 for controls; p < 0.0001). D COVID-19 articles were associated with lower NOS case–control score compared to historical control articles (n = 32 for COVID-19 and n = 32 for controls; p = 0.003). E COVID-19 articles were associated with higher diagnostic risk of bias (QUADAS-2) compared to historical control articles (n = 53 for COVID-19 and n = 53 for controls; p = 0.02). For panel A, boxplot captures 5, 25, 50, 75 and 95% from the first to last whisker. Orange represents COVID-19 articles and blue represents control articles. Two-sided Mann–Whitney U-test was conducted to evaluate differences in time to acceptance between COVID-19 and control articles. Differences in study quality scores were evaluated by two-sided Kruskal–Wallis test. Differences in diagnostic risk of bias were quantified by Chi-squares test. p < 0.05 was considered statistically significant.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

3 retracted

Show all 54 references

Cited by

See all 193

Metadata

Authors
Jung, R. G., Di Santo, P., Clifford, C., Prosperi-Porta, G., Skanes, S., Hung, A., Parlow, S., Visintini, S., Ramirez, F. D., Simard, T., & Hibbert, B.
Affiliations
  • University of Ottawa (CA)
  • Ottawa Hospital (CA)
  • Ottawa Heart Institute (CA)
  • Université de Bordeaux (FR)
  • Mayo Clinic (US)
Corresponding author
Hibbert, Benjamin
Venue
Nature Communications
Published
2021-02-11
Volume
12
Issue
1
Pages
943-943
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3128106047
Cited by
189
References
54
Citations by year
2026: 4 · 2025: 35 · 2024: 20 · 2023: 41 · 2022: 50 · 2021: 37
FWCI
7.21
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • medRxiv (acceptedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Royal College of Physicians and Surgeons of Canada
  • Canadian Institutes of Health Research
Topics
  • Social Sciences › Library and Information Sciences › Academic Publishing and Open Access
  • Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords
COVID-19 pandemic, methodological quality, clinical research, scientific rigor, time to publication, peer review, historical controls
MeSH terms
Clinical Studies as Topic, Data Accuracy, COVID-19, Animals, Humans, Periodicals as Topic, Research Design, Time Factors, Peer Review, Research, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Methodological quality of COVID-19 clinical research. https://app.cochat.ai/papers/10.1038/s41467-021-21220-5
The paper
Jung, R. G., Di Santo, P., Clifford, C., Prosperi-Porta, G., Skanes, S., Hung, A., Parlow, S., Visintini, S., Ramirez, F. D., Simard, T., & Hibbert, B. (2021). Methodological quality of COVID-19 clinical research. Nature Communications. https://doi.org/10.1038/s41467-021-21220-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.